Citations

Clear

6273 citation(s) found for "To, Andrew".

Utility of Protein Microarrays for Detection of Classified and Novel Antibodies in Autoimmune Neurologic Disease
Lesnick, Connie , Vorasoot, Nisa , Buckley, Monica , Dasari, Surendra , Gilligan, Michael , Lafrance-Corey, Reghann , Miske, Ramona , Pittock, Sean J. , Scharf, Madeleine, Yang, Binxia , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Mills, John R. , Pittock, S J , Lesnick, Connie , Vorasoot, Nisa , Buckley, Monica W , Dasari, Surendra , Gilligan, Michael , Lafrance-Corey, Reghann , Yang, Binxia , Dubey, Divyanshu , McKeon, Andrew , Flanagan, Eoin P.

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | August 7, 2023 | Volume: 10 | Issue: 5 | Pages: No page available

10.1212/nxi.0000000000200145 | PMID 37550073 Get It

Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Pappo, Alberto S. , Acquazzino, Melissa , Barnett, Marie , Casey, Robert, Choo, Sun , Dinner, Shira, Fair, Douglas , Federman, Noah , Folbrecht, Jeanelle , Gandhi, Shipra , Germann, Julie N. , Goldsby, Robert E. , Hayashi, Robert J. , Huang, Mary , Jacobs, Linda A. , Lee‐Miller, Cathy , Link, Michael P., Lustberg, Maryam B. , Malogolowkin, Marcio H., Oeffinger, Kevin C. , Pratilas, Christine A. , Mehren, Margaret von , Yeager, Nicholas D. , Hang, Lisa, von Mehren, Margaret , Lustberg, Maryam , Bhatia, Smita , Allen‐Rhoades, Wendy , Borinstein, Scott C. , Chugh, Rashmi , Ermoian, Ralph P. , Huang, Alex Yee-Chen , Livingston, J. Andrew , Reed, Damon R. , Skiles, Jodi L. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 851-880

10.6004/jnccn.2023.0040 | PMID 37549914 Get It

This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.
Association between early childhood sleep difficulties and subsequent psychiatric illness
Pease, Eric , Shekunov, Julia , Golebiowski, Raphael, Dang, Vanessa, Arbon, Jake, Lloyd, Robin M. , Baughn, Julie , Romanowicz, Magdalena , Savitz, Samuel T. , Lloyd, Robin, Dang, Vanessa, Pines, Andrew R.

Mayo Clinic

Journal of Clinical Sleep Medicine | August 4, 2023 | Volume: 19 | Issue: 12 | Pages: 2059-2063

10.5664/jcsm.10756 | PMID 37539644 Get It

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, Patrick Y. , Barboriak, Danial, DeGroot, John, Lassman, Andrew B. , Molinaro, Annette M. , Preusser, Mattias, Rahman, Rifaquat , Shankar, Lalitha , Sul, Joohee, Villanueva‐Meyer, Javier , Macdonald, David , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, Gilbert , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology Advances | August 4, 2023 | Volume: 5 | Issue: Supplement_3 | Pages: iii8-iii8

10.1093/noajnl/vdad070.029 Get It

Abstract The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve the reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and uncertainty emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. Informed by data from a cohort of glioblastoma patients and other evaluations of RANO criteria that allowed evaluation of features of the different criteria, we propose updates to the RANO criteria (RANO 2.0). Based on the 2021 WHO classification of gliomas, we recommend a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the post-radiotherapy MRI, rather than the post-surgical MRI, will be used as the baseline for future comparison. Since the incidence of pseudoprogression is high in the 12 weeks following radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, is required to define tumor progression. However, confirmation scans are not mandatory after this period nor for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is an option. The primary measurement remains the maximum cross-sectional area of tumor (2-dimensional) but volumetric measurements are an option. For IDH-wildtype glioblastoma, the non-enhancing disease will no longer be evaluated. In IDH-mutated tumors with a significant non-enhancing component, clinical trials may require evaluating both the enhancing and non-enhancing tumor components for response assessment.
Genome‐wide study of genetic polymorphisms predictive for outcome from first‐line oxaliplatin‐based chemotherapy in colorectal cancer patients
Park, Hanla A. , Canzian, Federico , Harrison, Tabitha A. , Hua, Xinwei , Shi, Qian , Silverman, Allison , Benner, Axel , Macauda, Angelica , Schneider, Martin , Goldberg, Richard M. , Brenner, Hermann , Peters, Ulrike , Chang‐Claude, Jenny , Canzian, Federico , Macauda, Angelica , Hoffmeister, Michael , Harrison, Tabitha A , Shi, Qian , Brenner, Hermann , Edelmann, Dominic , Seibold, Petra , Alberts, Steven R. , Hoffmeister, Michael , Chan, Andrew T. , Newcomb, Polly A.

Mayo Clinic

International Journal of Cancer | August 4, 2023 | Volume: 153 | Issue: 9 | Pages: 1623-1634

10.1002/ijc.34663 | PMID 37539667 Get It

AbstractWe conducted the first large genome‐wide association study to identify novel genetic variants that predict better (or poorer) prognosis in colorectal cancer patients receiving standard first‐line oxaliplatin‐based chemotherapy vs chemotherapy without oxaliplatin. We used data from two phase III trials, NCCTG N0147 and NCCTG N9741 and a population‐based patient cohort, DACHS. Multivariable Cox proportional hazards models were employed, including an interaction term between each SNP and type of treatment for overall survival (OS) and progression‐free survival. The analysis was performed for studies individually, and the results were combined using fixed‐effect meta‐analyses separately for resected stage III colon cancer (3098 patients from NCCTG N0147 and 549 patients from DACHS) and mCRC (505 patients from NCCTG N9741 and 437 patients from DACHS). We further performed gene‐based analysis as well as in silico bioinformatics analysis for CRC‐relevant functional genomic annotation of identified loci. In stage III colon cancer patients, a locus on chr22 (rs11912167) was associated with significantly poorer OS after oxaliplatin‐based chemotherapy vs chemotherapy without oxaliplatin (Pinteraction < 5 × 10−8). For mCRC patients, three loci on chr1 (rs1234556), chr12 (rs11052270) and chr15 (rs11858406) were found to be associated with differential OS (P < 5 × 10−7). The locus on chr1 located in the intronic region of RCSD1 was replicated in an independent cohort of 586 mCRC patients from ALGB/SWOG 80405 (Pinteraction = .04). The GWA gene‐based analysis yielded for RCSD1 the most significant association with differential OS in mCRC (P = 6.6 × 10−6). With further investigation into its biological mechanisms, this finding could potentially be used to individualize first‐line treatment and improve clinical outcomes.
Interplay of Impaired Cellular Bioenergetics and Autophagy in PMM2-CDG
Ligezka, Anna N. , Budhraja, Rohit , Nishiyama, Yurika, Fiesel, Fabienne C. , Preston, Graeme , Edmondson, Andrew C. , Ranatunga, Wasantha , Hove, Johan L.K. Van , Springer, Wolfdieter , Pandey, Akhilesh , Kozicz, Tamás , Watzlawik, Jens O. , Springer, Wolfdieter , Pandey, Akhilesh , Kozicz, Tamas , Fiesel, Fabienne C , Edmondson, Andrew C , Morava, Éva

Mayo Clinic

Genes | August 4, 2023 | Volume: 14 | Issue: 8 | Pages: 1585

10.3390/genes14081585 | PMID 37628636 Get It

Congenital disorders of glycosylation (CDG) and mitochondrial disorders are multisystem disorders with overlapping symptomatology. Pathogenic variants in the PMM2 gene lead to abnormal N-linked glycosylation. This disruption in glycosylation can induce endoplasmic reticulum stress, contributing to the disease pathology. Although impaired mitochondrial dysfunction has been reported in some CDG, cellular bioenergetics has never been evaluated in detail in PMM2-CDG. This prompted us to evaluate mitochondrial function and autophagy/mitophagy in vitro in PMM2 patient-derived fibroblast lines of differing genotypes from our natural history study. We found secondary mitochondrial dysfunction in PMM2-CDG. This dysfunction was evidenced by decreased mitochondrial maximal and ATP-linked respiration, as well as decreased complex I function of the mitochondrial electron transport chain. Our study also revealed altered autophagy in PMM2-CDG patient-derived fibroblast lines. This was marked by an increased abundance of the autophagosome marker LC3-II. Additionally, changes in the abundance and glycosylation of proteins in the autophagy and mitophagy pathways further indicated dysregulation of these cellular processes. Interestingly, serum sorbitol levels (a biomarker of disease severity) and the CDG severity score showed an inverse correlation with the abundance of the autophagosome marker LC3-II. This suggests that autophagy may act as a modulator of biochemical and clinical markers of disease severity in PMM2-CDG. Overall, our research sheds light on the complex interplay between glycosylation, mitochondrial function, and autophagy/mitophagy in PMM2-CDG. Manipulating mitochondrial dysfunction and alterations in autophagy/mitophagy pathways could offer therapeutic benefits when combined with existing treatments for PMM2-CDG.
IDH1 /2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience
Gangat, Naseema , Ajufo, Helen, Abdelmagid, Maymona, Karrar, Omer , Badar, Talha , Foran, James M. , Palmer, Jeanne , Mangaonkar, Abhishek A. , Rampal, Raajit K. , Tefferi, Ayalew , Badar, Talha , Foran, James M , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Kuykendall, Andrew , Tefferi, Ayalew , McCullough, Kristen , Alkhateeb, Hassan B.

Mayo Clinic

British Journal of Haematology | August 4, 2023 | Volume: 203 | Issue: 3 | Pages: No page available

10.1111/bjh.19027 | PMID 37537750 Get It

ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma
Feldman, Andrew L. , Feldman, Andrew L , Jaye, David L.

Mayo Clinic

Blood | August 3, 2023 | Volume: 141 | Issue: 17 | Pages: 2160-2160

10.1182/blood.2022019468 | PMID 37103947 Get It

Sex Differences in Resting Metabolic Rate among Athletes and Association with Body Composition Parameters: A Follow-Up Investigation
Jagim, Andrew R. , Jones, Margaret T. , Askow, Andrew T. , Luedke, Joel, Erickson, Jacob L. , Fields, Jennifer B. , Kerksick, Chad M. , Jagim, Andrew R , Kerksick, Chad M , Askow, Andrew T

Mayo Clinic

Journal of Functional Morphology and Kinesiology | August 3, 2023 | Volume: 8 | Issue: 3 | Pages: 109

10.3390/jfmk8030109 | PMID 37606404 Get It

The purpose of this study was to examine sex differences in resting metabolic rate (RMR) and associations between measured RMR and body composition parameters in athletes. One-hundred and ninety collegiate men (n = 98; age: 20.1 ± 1.6 yr.; body mass: 92.7 ± 17.5 kg; height: 181.6 ± 6.2 cm, body mass index: 28.0 ± 4.7 kg/m2) and women (n = 92; age: 19.4 ± 1.1 yr.; body mass: 65.2 ± 11.0 kg; height: 168.0 ± 6.6 cm, body mass index: 23.0 ± 3.6 kg/m2) athletes volunteered to participate in this study. Athletes completed a body composition assessment using air displacement plethysmography and RMR using indirect calorimetry. Assessments were completed in a fasted state and after refraining from intense physical activity > 24 h prior to testing. Data were collected during the 2016–2019 seasons. Men had a higher RMR compared to women (2595 ± 433 vs. 1709 ± 308 kcals; p < 0.001); however, when adjusted for body mass (p = 0.064) and fat-free mass (p = 0.084), the observed differences were not significant. Height, body mass, body mass index, fat-free mass, and fat mass were positively associated with RMR in both men and women athletes (r = 0.4–0.8; p < 0.001). Body mass (men: β = 0.784; women: β = 0.832)) was the strongest predictor of RMR. Men athletes have a higher absolute RMR compared to their women counterparts, which is influenced by greater body mass and fat-free mass. Body mass is the strongest predictor of RMR in both men and women athletes.
Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
Huamán, Moisés A. , Patel, Bela , Marshall, Christi E., Yarava, Anusha , Heath, Sonya L. , Fukuta, Yuriko , Blair, Janis E. , Spivak, Emily S , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Ram, Malathi , Das, Piyali, Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Laeyendecker, Oliver , Ehrhardt, Stephan , Lau, Bryan , Baksh, Sheriza , Shade, David , Ou, Jiangda , Gniadek, Thomas J. , Ziman, Alyssa , Bloch, Evan M. , Gerber, Jonathan M. , Ziman, Alyssa , Bloch, Evan M , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Laeyendecker, Oliver , Raval, Jay S. , Paxton, James H , Mosnaim, Giselle S , Anjan, Shweta , Meisenberg, Barry R. , Levine, Adam C , Shenoy, Aarthi , Currier, Judith S. , Broderick, Patrick B., Sutcliffe, Catherine G , Zand, Martin S. , Kassaye, Seble , Wang, Ying , Ford, Daniel E , Pekosz, Andrew , Klein, Sabra L , Casadevall, Arturo , Hanley, Daniel F. , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Transfusion | August 3, 2023 | Volume: 63 | Issue: 9 | Pages: 1639-1648

10.1111/trf.17485 | PMID 37534607 Get It

AbstractBackgroundCOVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials.Study Design and MethodsWe analyzed data pertaining to transfusion‐related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders.ResultsThe combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic‐type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients' underlying disease, COVID‐19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43–1.31). Risk of urticaria and/or pruritus increased with a pre‐existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16–4.67). We did not observe any CCP‐attributed antibody disease enhancement in participants with COVID‐19 or increased risk of infection. There were no life‐threatening severe transfusion reactions and no patients required hospitalization related to transfusion‐associated complications.DiscussionOutpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID‐19.